BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jansen H, Pape UF, Utku N. A review of systemic therapy in biliary tract carcinoma. J Gastrointest Oncol 2020;11:770-89. [PMID: 32953160 DOI: 10.21037/jgo-20-203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Andersen LB, Mahler MSK, Andersen RF, Jensen LH, Raunkilde L. The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab. Cancers 2022;14:4598. [DOI: 10.3390/cancers14194598] [Reference Citation Analysis]
2 Kang S, El-Rayes BF, Akce M. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2022;14:1748. [PMID: 35406520 DOI: 10.3390/cancers14071748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Phansila N, Sittiwet C, Wongkongdech R. Comparison of effects of medicinal cannabis or standard palliative care on quality of life of patients with cholangiocarcinoma in Northeast Thailand. F1000Res 2022;11:20. [DOI: 10.12688/f1000research.75060.1] [Reference Citation Analysis]
4 Hunter LA, Soares HP. Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:5074. [PMID: 34680223 DOI: 10.3390/cancers13205074] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 Tominaga H, Matsuzaki J, Oikawa C, Toyoshima K, Manabe H, Ozawa E, Shimamura A, Yokoyama R, Serizawa Y, Ochiya T, Saito Y. Challenges for Better Diagnosis and Management of Pancreatic and Biliary Tract Cancers Focusing on Blood Biomarkers: A Systematic Review. Cancers (Basel) 2021;13:4220. [PMID: 34439378 DOI: 10.3390/cancers13164220] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Du F, Qiu Z, Ai W, Huang C, Ji J, Xiao X, Zhou J, Fang M, Jiang X, Gao C. Blood tests predict the therapeutic prognosis of anti-PD-1 in advanced biliary tract cancer. J Leukoc Biol 2021;110:327-34. [PMID: 33724548 DOI: 10.1002/JLB.5MA1220-631R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pape UF, Kasper S, Meiler J, Sinn M, Vogel A, Müller L, Burkhard O, Caca K, Heeg S, Büchner-Steudel P, Rodriguez-Laval V, Kühl AA, Arsenic R, Jansen H, Treasure P, Utku N. Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study. Cancers (Basel) 2020;12:E3149. [PMID: 33121007 DOI: 10.3390/cancers12113149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]